Trial Profile

A Phase II Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Paricalcitol as Pre-operative Treatment in Patients With Untreated Resectable, Borderline Resectable and Locally Advanced Adenocarcinoma of the Pancreas

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary) ; Paricalcitol (Primary)
Indications Adenocarcinoma; Pancreatic cancer; Pancreatic ductal carcinoma
Focus Therapeutic Use

22 Apr 2026 Number of treatment arms changed from 1 to 2, primary endpoint time frame changed from 63 days to 26 weeks, patient number changed from 24 to 40 and treatment allocation was changed to Non-Randomized, hence protocol was amended.
22 Apr 2026 Actual primary completion date changed from 3 Mar 2024 to 13 Jul 2023.
22 Apr 2026 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com